← Back to Clinical Trials
Recruiting NCT07627139

NCT07627139 Metacognitive Bibliotherapy for Anxiety, Depression, and Metacognitions in University Students

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07627139
Status Recruiting
Phase —
Sponsor Istanbul Nisantasi University
Condition Anxiety
Study Type INTERVENTIONAL
Enrollment 165 participants
Start Date 2026-10-19
Primary Completion 2027-01-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Zihninde Çok Kuran İnsanlar için Salma RehberiÇapa Atmak

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 165 participants in total. It began in 2026-10-19 with a primary completion date of 2027-01-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study tests whether reading a structured self-help book (bibliotherapy) can reduce anxiety, depression and stress and change unhelpful thinking patterns in medical and health-sciences students. Students in health programs face heavy academic and clinical demands and are at increased risk of emotional distress. A thinking style called the Cognitive Attentional Syndrome (worry, rumination, threat monitoring and unhelpful coping) is thought to link stress to anxiety and depression. Metacognitive therapy targets this thinking style, and low-intensity self-help books may make these principles accessible to students. A total of 165 students at İstanbul Nişantaşı University will be randomly assigned to one of three groups: two groups each receive a different self-help book and read it at their own pace over 8 weeks, and the third group (waitlist) receives the books after the study ends. All participants complete short online questionnaires (DASS-21, CAS-1, MCQ-30) at the start, at week 4 and at week 8, and receive brief telephone calls at weeks 2, 4 and 6 to confirm participation.

Eligibility Criteria

Inclusion Criteria: * Age 18 years or older * Currently enrolled as a student in a medicine or health-sciences program (medicine, psychology, nursing and dentistry) at İstanbul Nişantaşı University * Sufficient proficiency in reading and understanding Turkish * Access to an internet-connected device to complete online forms * Electronic informed consent Exclusion Criteria: * Currently receiving active psychiatric treatment (psychotherapy or psychotropic medication) * Change in psychotropic medication within the last 6 months * Having previously read either of the study books * Diagnosis of bipolar disorder * Acute psychotic symptoms or current suicide risk

Contact & Investigator

Central Contact

Alişan Burak Yaşar, MD, Assoc. Prof.

✉ alisanburak.yasar@nisantasi.edu.tr

📞 +90 532 424 30 58

Frequently Asked Questions

Who can join the NCT07627139 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07627139 currently recruiting?

Yes, NCT07627139 is actively recruiting participants. Contact the research team at alisanburak.yasar@nisantasi.edu.tr for enrollment information.

Where is the NCT07627139 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07627139 clinical trial?

NCT07627139 is sponsored by Istanbul Nisantasi University. The trial plans to enroll 165 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology